Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.

2.

Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.

Taal W, van der Rijt CC, Dinjens WN, Sillevis Smitt PA, Wertenbroek AA, Bromberg JE, van Heuvel I, Kros JM, van den Bent MJ.

J Neurooncol. 2015 Jan;121(2):365-72. doi: 10.1007/s11060-014-1641-9. Epub 2014 Oct 26.

PMID:
25344884
3.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ.

Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.

PMID:
25035291
4.

Bortezomib-induced polyneuropathy.

Rampen AJ, Jongen JL, van Heuvel I, Scheltens-de Boer M, Sonneveld P, van den Bent MJ.

Neth J Med. 2013 Apr;71(3):128-33.

5.

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.

Taal W, Segers-van Rijn JM, Kros JM, van Heuvel I, van der Rijt CC, Bromberg JE, Sillevis Smitt PA, van den Bent MJ.

J Neurooncol. 2012 May;108(1):195-200. doi: 10.1007/s11060-012-0832-5. Epub 2012 Mar 7.

6.

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.

Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Kros JM, Kouwenhoven MC, van Marion R, van Heuvel I, van der Holt B, Bromberg JE, Sillevis Smitt PA, Dinjens WN, van den Bent MJ; Dutch Society for Neuro-Oncology.

Neuro Oncol. 2011 Feb;13(2):235-41. doi: 10.1093/neuonc/noq177. Epub 2010 Dec 21.

7.

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ.

Neurology. 2009 Nov 24;73(21):1792-5. doi: 10.1212/WNL.0b013e3181c34ace.

PMID:
19933982
8.

[Favourable result for temozolomide in recurrent high-grade glioma].

Taal W, van der Rijt CD, Sillevis Smitt PA, Kros JM, van Heuvel I, Enting RH, van den Bent MJ.

Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1393-9. Dutch.

PMID:
15997692
9.

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.

Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ.

Cancer. 2005 Feb 15;103(4):802-9.

10.

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.

Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A, Kros JM, Stege EB, Enting RH, Allgeier A, van Heuvel I, van den Bent MJ.

Neurology. 2004 Sep 14;63(5):904-6.

PMID:
15365146

Supplemental Content

Loading ...
Support Center